clinical trial · NCT05279300
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Advanced Solid TumorAdvanced LymphomaCS5001RituximabGemcitabineOxaliplatinLenalidomideCyclophosphamideDoxorubicinVincristine
brief summary
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid tumors.
started
Mar 28, 2022
primary completion
Jun 30, 2027
completion
Dec 31, 2027
last updated
Aug 11, 2025
official title
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5001, an Anti-ROR1 Antibody-Drug Conjugate, Used as A Single Agent and in Combination With Systemic Therapies in Patients With Advanced Solid Tumors and Lymphomas
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol